A Single Intravenous Dose of Ivabradine, a Novel If Inhibitor, Lowers Heart Rate but Does Not Depress Left Ventricular Function in Patients with Left Ventricular Dysfunction
Open accessThe DOI matches its Crossref record.
Abstract
This randomized, single-blind, placebo-controlled study investigated the effect of ivabradine, a novel heart rate-lowering agent, on echocardiographic indices of left ventricular (LV) systolic function in patients with regional (coronary artery disease) or global (cardiomyopathy) LV dysfunction. Patients were randomized on an unequal basis to receive ivabradine 0.25 mg/kg (n = 31) or placebo (n = 13) by intravenous infusion. Resting heart rate was reduced by a mean of 17.6 ± 4.7% with ivabradine and 1.5 ± 5.8% with placebo. The mean maximum decrease in LV ejection fraction was 0.2% with ivabradine and 1.7% with placebo. Fractional shortening and stroke volume were also fully preserved after ivabradine administration. Thus, a single intravenous dose of ivabradine produced a substantial reduction in resting heart rate without affecting LV function in patients with regional or global LV dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations
Boudoulas, K. D., Borer, J. S., & Boudoulas, H. (2015) · Cardiology · doi:10.1159/000435947 · Cited by 1,938
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,555
Fox, K., Ford, I., Steg, P. G., Tendera, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61170-8 · Cited by 1,099
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
DiFrancesco, D., & Camm, J. A. (2004) · Drugs · doi:10.2165/00003495-200464160-00003 · Cited by 409
Tardif, J.-C., Ponikowski, P., Kahan, T., & for the ASSOCIATE study Investigators (2009) · European Heart Journal · doi:10.1093/eurheartj/ehn571 · Cited by 340
Clinical Efficacy of Ivabradine in Patients With Inappropriate Sinus Tachycardia
Cappato, R., Castelvecchio, S., Ricci, C., Bianco, E., Vitali-Serdoz, L., Gnecchi-Ruscone, T., Pittalis, M., De Ambroggi, L., Baruscotti, M., Gaeta, M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.031 · Cited by 159
“The recent introduction of ivabradine (10,11), a specific If blocker with no interactions with the cardiovascular system, has provided investigators with the unique opportunity to test the impact of pure If blockade on cardiac chronotropy and the variable symptoms associated with this syndrome.”
BackgroundHCN Channels Modulators: The Need for Selectivity
Novella Romanelli, M., Sartiani, L., Masi, A., Mannaioni, G., Manetti, D., Mugelli, A., & Cerbai, E. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616999160315130832 · Cited by 73
Ivabradine in patients with inappropriate sinus tachycardia
Zellerhoff, S., Hinterseer, M., Felix Krull, B., Schulze-Bahr, E., Fabritz, L., Breithardt, G., Kirchhof, P., & Kääb, S. (2010) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-010-0565-y · Cited by 52
Metadata
- Authors
- Manz, M., Reuter, M., Lauck, G., Omran, H., & Jung, W.
- Venue
- Cardiology
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 100
- Issue
- 3
- Pages
- 149-155
- ISSN
- 0008-6312 (ISSN-L)
- 1421-9751
- OpenAlex
- W1999660133
- Cited by
- 156
- References
- 0
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.